| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0098 | 0.9 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.9 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |